To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510644-31-00

Acronym

GO43073

Enrollment

Registered

2024-04-17

Start date

2022-06-10

Completion date

2024-05-14

Last updated

2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark, Norway, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026